HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
07. November 2024 08:00 ET
|
HilleVax, Inc.
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in...
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
08. August 2024 19:20 ET
|
HilleVax, Inc.
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine...
HilleVax Announces Reduction in Force
31. Juli 2024 16:00 ET
|
HilleVax, Inc.
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
08. Juli 2024 07:30 ET
|
HilleVax, Inc.
The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the...
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
09. Mai 2024 16:05 ET
|
HilleVax, Inc.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May ...
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
20. März 2024 16:00 ET
|
HilleVax, Inc.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and...
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
05. Februar 2024 16:05 ET
|
HilleVax, Inc.
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
18. Januar 2024 07:00 ET
|
HilleVax, Inc.
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
08. Januar 2024 07:00 ET
|
HilleVax, Inc.
BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and...
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03. Januar 2024 18:28 ET
|
HilleVax, Inc.
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...